PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Balsalazide sodium - Inflammatory bowel disease
PAD Profile : Balsalazide sodium - Inflammatory bowel disease
Keywords :
Ulcerative colitis, UC, IBD, Chronic Bowel Disorders, Inflammatory Bowel Disease
Brand Names Include :
Colazide
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Azathioprine
- Infliximab
- Mercaptopurine
- Ciclosporin
- Golimumab
- Vedolizumab
- Allopurinol
- Prednisolone
- Budesonide
- Tofacitinib
- Methotrexate
- Mesalazine (Systemic)
- Filgotinib
- Sulfasalazine
- Upadacitinib
- Risankizumab
- Olsalazine sodium
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
13 June 2016
Not Set
This drug / device has not yet been evaluated by NICE or the Surrey and Sussex Prescribing Clinical Network (PCN). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.
This drug is currently not on the PCN workplan. The PCN will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.
Associated BNF Codes
01. Gastro-Intestinal System
01.05.01. Aminosalicylates